| Display title | Chemistry:Cangrelor |
| Default sort key | Cangrelor |
| Page length (in bytes) | 15,169 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 246906 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>AstroAI |
| Date of page creation | 08:59, 8 February 2024 |
| Latest editor | imported>AstroAI |
| Date of latest edit | 08:59, 8 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Cangrelor, sold under the brand name Kengreal among others, is a P2Y12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. Unlike... |
